PCA3/KLK3 (prostate cancer antigen 3/kallikrein-related peptidase 3) ratio
The PCA3/KLK3 (prostate cancer antigen 3/kallikrein-related peptidase 3 ratio is determined by the PCA3 test which measures PCA3 mRNA in urine samples as a risk assessment tool for prostate cancer. Due to the widespread use of prostate-specific antigen (PSA) as a screening and diagnostic test for prostate cancer, it is the most frequently diagnosed cancer in men. PSA is an androgen regulated serine protease encoded by the KLK3 gene. It is secreted exclusively by prostate epithelial cells, and the serum concentration is very low in men with a healthy prostate. However, serum PSA level may be elevated not only in prostate cancer but also in noncancerous conditions such as prostatic inflammation, benign prostate hyperplasia, and urinary tract infection. A serum PSA level of 4.0 ng/mL or greater is viewed as the level for which further evaluation or biopsy is warranted. However, the positive biopsy rates are only about 25% in men with a PSA levels between 4–10 ng/mL These low-positive PSA results may lead to unnecessary biopsy, which is associated with bleeding and infection. False-negative results also occur; 20% to 25% of patients with prostate cancer have a PSA level less than 4.0 ng/mL Another disadvantage of PSA is its inability to discriminate low-grade, low-stage indolent tumors from more aggressive disease. Treatment of indolent cancer may negatively affect patient’s life qualities by causing psychological distress, side effects, or complications.
Therefore, more specific and sensitive biomarkers are needed for more accurate diagnosis of prostate cancer and to distinguish indolent from clinically significant tumors to reduce the number of repeat biopsies. Among the numerous novel biomarkers identified in an effort to overcome these weaknesses of PSA, prostate cancer antigen 3 (PCA3) is one of the most promising. The PCA3 gene located on 9q21-22 produces a long noncoding RNA. the PC3A RNA and protein are overexpressed in prostate cancer cells but not in benign prostate tissue or other types of normal tissue or tumors. The PCA3 test is a molecular assay that detects the increased mRNA prostate cells found in urine samples after digital rectal exam (DRE). The PCA3 test is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. The specificity and sensitivity of this testing for prostate cancer was found to be 78% and 57% respectively, in cancer vs. non-cancer. FDA approved this test in February 2012 to aid in the decision for a repeat prostate biopsy.
- To aid in guiding biopsy decision among men with prior negative prostate biopsies
- Treatment selection and disease management
Positive
- Positive PCA3 score. A score greater than or equal to 25 is considered positive. Positive result is associated with increased likelihood of a positive biopsy for cancer.
Negative
- Negative PCA3 score. A score less than 25 is considered negative. Negative result is associated with decreased likelihood of a positive biopsy for cancer.
- 0-17: Negative - Result associated with decreased likelihood of a positive biopsy for cancer
- 18-24: Negative - Result should be interpreted with caution. Due to normal test variability, specimen with PCA3 scores near the cut-off may yield a different overall interpretation upon repeat testing
- 25-31: Positive – Result should be interpreted with caution. Due to normal test variability, specimen with PCA3 scores near the cut-off may yield a different overall interpretation upon repeat testing
- >31: Positive – Result associated with increased likelihood of a positive biopsy for cancer
20-30 mL first catch urine following DRE in preservative-free urine collection cup. Invert urine container 5-6 times to mix.
Transfer 2.5 mL urine within 4 hours of collection into two Progensa PCA3 Urine Specimen Transport Tubes.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 3 months
- Prostate Cancer. 2020 Jan 31;2020:3964615. [PMID: 32099679]
- Transl Oncol. 2018 Jun; 11(3): 628–632. [PMID: 29574327]
- Rev Urol. 2017;19(4):221-234. [PMID: 29472826]
- Clin Chem Lab Med. 2016 Mar;54(3):483-92. [PMID: 26630694]
- Neoplasia. 2013 Apr; 15(4): 448–453. [PMID: 23555189]
- Wright, C. M. (2015). Long Noncoding RNAs and Cancer.In: Chapter 5. Epigenetic Cancer Therapy, 91–114. doi:10.1016/b978-0-12-800206-3.00005-7.